Download Pdf: MIMS Ireland ESC 2013 guidelines CV risk assessment Table 1: Risk assessment table* Other risk factors, asymptomatic organ damage or disease ** Blood Pressure (mmHg) High normal SBP 130-139 or DBP 85-89 Grade 1 HT SBP 140-159 or DBP 90-99 Grade 2 HT SBP 160-179 or DBP 100-109 Grade 3 HT […]
ESH/ESC 2013 Guidelines – Stratification of total cardiovascular risk
December 13, 2013 by Leave a Comment
ESH/ESC Hypertension Guidelines 2013 – Treatment initiation
December 13, 2013 by Leave a Comment
Download Pdf: MIMS Ireland ESC 2013 guidelines – treatment initiation Table 3: Initiation of lifestyle changes and antihypertensive drug treatment Other risk factors, asymptomatic organ damage or disease Blood Pressure (mmHg) High normal SBP 130-139 or DBP 85-89 Grade 1 HT SBP 140-159 or DBP 90-99 Grade 2 HT SBP 160.-179 or DBP 100-109 Grade […]
Restrictions to the use of SABAs in obstetric indications
December 13, 2013 by Leave a Comment
Restrictions to the use of Short Acting Beta Agonists in obstetric indications The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of Short Acting Beta Agonists (SABAs) in obstetric indications. The Committee recommended that these agents no longer be used in oral or suppository forms in obstetric indications, such as […]
List of medicines under additional monitoring
December 13, 2013 by Leave a Comment
The European Union (EU) has introduced a new process to label medicines that are being monitored particularly closely by regulatory authorities. These medicines are described as being under ‘additional monitoring’. Download Pdf: MIMS Ireland – List of Medicines under Additional monitoring Additional monitoring status is always applied to a medicine in the following cases: • […]
Medicines subject to additional monitoring requirements
December 12, 2013 by Leave a Comment
All medicines are authorised on the basis that at the time of authorisation the benefit of treatment is judged to outweigh the potential harm in the specified indication(s) for the target population(s). However, not all risks can be identified at the time of initial authorisation and many of the risks associated with the use of […]
Colobreathe
December 1, 2013 by Leave a Comment
Company: Forest Laboratories UK Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Colistimethate sodium 125mg. Description: Hard transparent gelatin capsules containing white inhalation powder. Presentation: 56, €1105. Indication: Management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Pharmacology: Colistimethate sodium is a cyclic polypeptide antibacterial agent derived from Bacillus […]
Dexketoprofen Rowex
December 1, 2013 by Leave a Comment
Company: Rowex Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Dexketoprofen (as trometamol) 25mg. Description: White, biconvex, cylindric-shaped film-coated tablets marked DT2 on one side and can be divided into equal doses. Presentation: 50, €5.97. Indications: Mild to moderate pain such as musculoskeletal pain, dysmenorrhoea, dental pain. Pharmacology: Dexketoprofen trometamol is an analgesic, anti-inflammatory […]
Ultibro Breezhaler
December 1, 2013 by Leave a Comment
Company: Novartis Ireland Ltd. Legal category: Prescription. GMS. Sport prohibited. Active ingredients: Indacaterol 85μg/glycopyrronium 43μg per delivered dose. Description: Hard capsules with transparent yellow cap and natural transparent body containing white inhalation powder, marked with IGP110.50 under two blue bars on body and company logo on cap. Presentation: 30 capsule pack with one inhaler, €51.00. […]
Zyclara
December 1, 2013 by Leave a Comment
Company: Meda Health Sales. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Imiquimod 3.75%. Description: White to faintly yellow cream in single use sachets. Presentation: 28 sachets, €120.96. Indications: Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical […]
New Indication for Eylea
December 1, 2013 by Leave a Comment
Bayer Healthcare wishes to announce that Eylea (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to macular oedema secondary to Central Retinal Vein Occlusion (CRVO). Eylea is an intravitreal vascular endothelial growth factor (VEGF) decoy receptor. VEGF is increased in the ocular fluids of patients with CRVO […]
Loading ...
